Comparison of the Effects of Two Kinase Inhibitors, Sorafenib and Dasatinib, on Chronic Lymphocytic Leukemia Cells

Publisher： Karger

E-ISSN： 2296-5262|35|7-8|420-426

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.35, Iss.7-8, 2012-07, pp. : 420-426

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of phosphatidylinositol‐3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells

By  

INTERNATIONAL JOURNAL OF CANCER, Vol. 137, Iss. 9, 2015-11 ,pp. : 2234-2242

John Wiley & Sons Inc

Access to resources Recommend Favorite

Response to Dasatinib in a Patient with Concomitant Chronic Myeloid Leukemia and Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 105-109

Karger

Access to resources Recommend Favorite

Unsuccessful Dasatinib Therapy in a Refractory Patient with Chronic Lymphocytic Leukemia

By  

Acta Haematologica, Vol. 124, Iss. 2, 2010-08 ,pp. : 103-104

Karger

Access to resources Recommend Favorite

Dasatinib in the Treatment of Chronic Myeloid Leukemia

By  

Current Signal Transduction Therapy, Vol. 6, Iss. 1, 2011-01 ,pp. : 99-105

Bentham Science Publishers

Access to resources Recommend Favorite

Dasatinib for the treatment of chronic phase chronic myeloid leukemia

By Campbell Victoria   Copland Mhairi  

Clinical Practice, Vol. 10, Iss. 4, 2013-07 ,pp. : 415-425

Future Medicine

Access to resources Recommend Favorite